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Abstract:  Keratoconus is a condition characterized by  biomechanical instability of the cornea, presenting in a 
progressive, asymmetric and  bilateral way. Corneal collagen cross-linking with riboflavin and UVA (CXL) is a new 
technique of corneal tissue strengthening that combines the use of riboflavin as a photo sensitizer and UVA irradiation. 
The studies showed that CXL was effective in halting the progression of keratoconus over a period of up to four years. 
The published studies also revealed a reduction of max K readings by more than 2 D, while the postoperative SEQ was 
reduced by an average of more than 1 D, and refractive cylinder decreased by about 1 D. No eyes lost any line of 
BCDVA. Moreover, there was no significant decrease in endothelial cell density. It was also found that CXL treatment 
was effective with reducing corneal and total wavefront aberrations. Corneal cross-linking has also led to an arrest and/or 
even a partial reversal of keratectasia in the treatment of iatrogenic ectasia after excimer laser ablation. A primary 
intervention such as CXL should be considered to potentially increase the biomechanical stability of the corneal tissue and 
postpone the need of lamellar or penetrating keratoplasty. 
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INTRODUCTION 
  Keratoconus is a condition characterized by biomecha-
nical instability of the cornea, presenting in a progressive, 
asymmetric and bilateral way. The prevalence in general 
population is 50-200 per 100 000 [1]. A 20% of keratoconic 
patients will suffer of severe visual deterioration due to 
irregular astigmatism, myopia and corneal scarring, and 
optical means such as spectacles and rigid gas permeable 
contact lenses do not offer any visual rehabilitation [1]. 
  Corneal collagen cross-linking with riboflavin and UVA 
(CXL) is a new technique of corneal tissue strengthening 
that combines the use of riboflavin and UVA irradiation. 
Riboflavin works as a photo sensitizer for the induction of 
cross links between collagen fibrils and at the same time act 
as a shield from the penetration of UVA in the underlying 
tissues [2]. A primary intervention, such as CXL should be 
considered to potentially increase the biomechanical stability 
of the corneal tissue and postpone the need of lamellar or 
penetrating keratoplasty. 
CLINICAL RESULTS 
 The  first  in vivo controlled clinical study by Wollensak et 
al. included 23 eyes with moderate or advanced progressive 
keratoconus. The study showed that CXL was effective in 
halting the progression of keratoconus over a period of up to 
four years [3]. In this study, a mean preoperative progression 
of keratometry (max K) by 1.42 D in 52% of eyes over a 6-
month period immediately prior to the treatment was   
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followed by a postoperative decrease in 70% of eyes. The 
statistics also revealed a reduction of max K readings by 
2.01 D, while the postoperative SEQ was reduced by an 
average of 1.14 D. At the same time, 22% of the untreated 
fellow control eyes had a postoperative progression of 
keratectasia by an average of 1.48 D. 
  In another study, conducted by Jankov et al., it was found 
an arrest in the progression of keratoconus in a group of 
patients after CXL treatment. In a period of six months prior 
to the treatment all patients of this group presented a 
deterioration in terms of astigmatism and corneal stability. 
Max K readings decreased by more than 2 D (from 53.02 ± 
8.42 to 50.88 ± 6.05 D), SEQ in less than 1 D (from -3.27 ± 
4.08 to -2.68 ± 3.02 D), while refractive cylinder decreased 
by less 0.5 D (from -2.29 ± 1.77 to -1.86 ± 0.92 D). No eyes 
lost any line of BCDVA, 12 maintained the preoperative 
BCDVA, 7 gained one line, 5 gained two lines, and 1 patient 
gained three lines of BCDVA [4]. 
  Agrawal, in his study found similar results among an 
Indian population of 37 eyes after one year of follow up, 
with 54% of the eyes gaining at least one line of BCDVA, 
astigmatism decreased by mean of 1.2D in 47%, K value of 
the apex decreased by mean of 2.73 D in 66% eyes and 
maximum K value decreased by a mean of 2.47D in 54% of 
eyes [5]. 
  In their preliminary results Wittig-Silva et al., found 
similar results regarding BCDVA and K reading, with no 
difference in spherical equivalent and endothelial cell density 
between treated and control eyes after 12 months follow-up 
[6]. Vinciguerra et al., also found CXL treatment effective 
with reducing corneal and total wavefront aberrations one 
year after treatment [7]. 20    The Open Ophthalmology Journal, 2011, Volume 5  Jankov et al. 
  Corneal cross-linking has also been used successfully in 
the treatment of iatrogenic ectasia after excimer laser 
ablation. In a recently published study, CXL was performed 
in ten patients with a formerly undiagnosed forme fruste 
keratoconus or pellucid marginal corneal degeneration that 
underwent LASIK for the correction of myopic astigmatism 
and subsequently developed iatrogenic keratectasia [8]. CXL 
led to an arrest and/or even a partial reversal of keratectasia 
over a postoperative follow-up period of up to 25 months as 
demonstrated by pre- and postoperative corneal topography 
and reduction of maximal K-readings. 
  CXL treatment has an arresting effect in the progression 
of keratoconus. A small regression occurring may be 
explained as an effect of the rearrangement of corneal 
lamellae and the surrounding matrix [2]. Due to an increased 
number of cross-linking sites within the collagen molecule 
after CXL, stiffer fibrils and lamellae are likely generated. 
This process produces a rearrangement of corneal lamellae 
and the consequent relocation of the surrounding matrix, 
which, in turn, results in the reduction of the central corneal 
curvature. 
  Considering the collagen turnover in the cornea of 
several years, it is yet to be seen in the long-term studies 
whether the repeated treatment may be necessary. 
CONCLUSIONS 
  Keratoconus is a progressive ectatic disorder leading to 
visual deterioration due to irregular astigmatism and in 
advanced cases corneal scarring. Until recently, treatment 
options included spectacles, rigid gas permeable contact 
lenses and Intracorneal ring segments. Corneal Collagen 
cross- linking (CXL) with Riboflavin and UVA irradiation is 
a minimal invasive technique that modifies corneal stromal 
structures and increases corneal stability. From the studies 
presented in the manuscript, it is shown the arresting effect 
of CXL in keratoconic patients. It is also proved the efficacy 
of the procedure in reducing the corneal curvature, spherical 
equivalent refraction and refractive cylinder in keratoconic 
eyes after the application of CXL. The safety of the method 
is also demonstrated from the fact that there was no 
discrepancy in terms of endothelial cell density between 
treated and no treated eyes. 
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